MenuClose
Clinical Need
HG-CT-1 (CAR-T)
CDX

Pipeline

Blood cancers affect over 1.1 million people in the United States annually, with over 156,000 new cases estimated in 2014 alone.

  • The only curative treatment is an allogeneic HSCT with less than a 50% success rate in patients with chemo-refractory disease​
  • Most patients lack sensitivity to currently available therapies ​
  • Poor outcomes following allogeneic HSCT  
    • A novel third-generation HEMO-CAR-T (Anti-FLT3 CAR-T cells) to eliminate malignancy in patients with FLT3+ R/R AML
    • A novel bispecific monoclonal antibody CDX (FLT3-CD3) to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant​

    After exhausting all options, including chemotherapy, radiation therapy and immunotherapy, Hemogenyx Pharmaceuticals seeks to tackle the dangers and limitations associated with the current standard of care with its revolutionary technology.

    HG-CT-1 (CAR-T)

    Autologous 3rd-generation CAR-T therapies

    Mechanism of Action: cytotoxic lymphocyte (CTL)-mediated cytolysis

    • Clinically proven safety
    • Established Freedom to Operate

    HG-CT-1

    • Targeting FMS-like tyrosine kinase 3 receptor (FLT3), which is highly expressed by AML blasts in a majority of patients
    • Improved vector design for safety
    • Proprietary anti-FLT3 humanized antibody (scFv)
    • No off-target binding other than FLT3
    • No FLT3 Ligand (FLT3L) competition, avoiding possible reduction of HG-CT-1 efficacy
    • Proven in vitro and in vivo antitumor activity
    • Phase 1 clinical trial is in progress

    CDX

    Efficacy – Anti-FLT3 ‘arm’ of CDX does not compete with the FLT3 Ligand expressed by a variety of cell types on their surface including AML, avoiding possible reduction of the antibody efficacy since no competition with endogenous ligand​

    Safety – CDX does not activate T cells in the absence of target cells.

    Market Expansion – Effective and non-toxic conditioning will extend the use of BM/HSC transplantation to older and more frail patients and potentially target several additional indications including autoimmune and rare genetic disorders

    Blue: scFv are anti-FLT3 portion of the bispecific antibody.

    Red: anti-CD3 portion of the bispecific antibody